The efficacy and safety of early, low frequency antiresorptive drug intervention for osteopaenia on bone mineral density (BMD) and bone turnover in Chinese post-menopausal women at risk of developing osteoporosis were investigated. A total of 180 women aged 40 -70 years were enrolled and equally randomized to receive either 70 mg alendronate once every 2 weeks plus 0.5 µg alfacalcidol daily (treatment group) or alfacalcidol 0.5 µg daily alone (control group) for 12 months. In the treatment group, lumbar spine and total hip BMD at 12 months had increased significantly from baseline and compared with the control group. There were also significant reductions in serum levels of the bone turnover biomarkers, bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen, compared with the control. No serious adverse events were observed in either group and safety profiles were similar. It was concluded that early intervention with 70 mg alendronate once every 2 weeks was safe, well tolerated and more effective than alfacalcidol alone (control) in increasing BMD and reducing bone turnover, and might prevent serious outcomes, such as fragility fractures, reduce rates of adverse effects and improve patient compliance.
Introduction
Osteopaenia is a disorder in which bone resorption exceeds bone formation, resulting in bone mineral density (BMD) being lower than normal and it is frequently viewed as a precursor to osteoporosis. Specifically, the World Health Organization's (WHO) definition of osteopaenia is a BMD of between -1.0 and -2.5 SDs below the mean for healthy young adults (T-score between -1.0 and -2.5). 1 Osteopaenia results in fragile bones and increased risk of fractures. 2 That risk becomes even higher if patients develop osteoporosis, but not all patients do; the L You, Z-Y Sheng, J-Y Chen et al. Low-dose alendronate therapy for osteopaenia incidence of osteopaenia is considerably higher than that of osteoporosis and most fractures in patients with low BMD occur in those with osteopaenia. 3, 4 Effective treatment of osteopaenia before the development of osteoporosis would be of great clinical importance and would also be economically relevant, as early therapeutic intervention for low bone mass decreases the risk of bone fractures and, therefore, their associated medical costs. 5 Whether patients who have osteopaenia but no fractures should be treated with antiresorptive drugs, however, remains controversial; 6 -9 data on use of antiresorptive drugs in this way are scant.
Alendronate is a potent inhibitor of bone absorption. 10, 11 It is a nitrogen-containing bisphosphonate that has been widely used as a first-line drug in the treatment of osteoporosis in post-menopausal women. Studies have shown that regimens of 10 mg daily or 70 mg once weekly increase bone mass, decrease the rate of bone turnover and reduce the risk of fracture. 12 -16 Researchers have investigated whether lower or lessfrequent dosing might remain efficacious in the treatment of osteoporotic patients in order to try to reduce treatment costs and improve patient adherence through increased patient convenience. For example, in a study in Japan, 5 mg alendronate daily or 35 mg once weekly was shown to increase BMD in patients with osteoporosis. 17 The 5 mg and 35 mg forms of alendronate are unavailable in China, whereas the regular regimens of 10 mg daily or 70 mg once weekly are used. Although 10 mg alendronate daily effectively prevents osteoporosis, it is not widely used in China among women at risk of developing osteoporosis. According to current data from the marketing and consulting organization, the IMS Group, sales of alendronate 10 mg in China are much lower than those of the 70 mg form (12.7% versus 87.3%, respectively) and the 10 mg form is also much less prescribed in hospitals. This may be because the 10 mg daily dosing is viewed as less convenient although, whether a less frequent 70 mg regimen, i.e. once every 2 weeks, would be beneficial and more acceptable in China among women at risk of developing osteoporosis is unclear. Recommendations for drug intervention thresholds in women with osteopaenia and no history of fracture are inconsistent, 2,3,18 especially for T-scores between -1.6 and -2.4, as no optimum threshold for starting antiresorptive therapy has been universally accepted. 19 This study investigated the efficacy and tolerability of 70 mg alendronate once every 2 weeks on BMD and bone turnover in Chinese post-menopausal women with osteopaenia who were at risk of osteoporosis. Women with osteopaenia rather than those with osteoporosis were chosen so as to determine the effects of early intervention using this regimen. Alendronate treatment was combined with alfacalcidol, a vitamin D analogue, and compared with alfacalcidol alone. Alfacalcidol was used rather than a placebo because alfacalcidol is used as the basal treatment for patients diagnosed with osteopaenia and it would be unethical to leave these patients untreated.
Patients and methods

PATIENTS AND STUDY DESIGN
This study was a 12-month, randomized, prospective, controlled clinical trial. Patients were recruited from the Outpatient Clinic of Shanghai First People's Hospital from May to December 2008. Eligible participants were post-menopausal Chinese women aged < 70 years with osteopaenia (T-score between -1.6 and -2.4). Patients who in the previous 6 months to the start of the study had been diagnosed with secondary osteoporosis, L You, Z-Y Sheng, J-Y Chen et al. Low-dose alendronate therapy for osteopaenia other bone diseases, reflux oesophagitis, gastric or duodenal diseases, gastrectomy, diseases that affect bone metabolism (diabetes mellitus, primary hyperparathyroidism, hyperthyroidism), serious renal or hepatic diseases and those who had received glucocorticoids could be included in the study. Exclusion criteria were history of fragility fracture or ever having received previous treatment for osteoporosis.
Ethics approval was obtained from the Ethics Committee of Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China. All patients gave written, informed consent before undergoing the study protocol. The primary endpoint was increase in BMD and the secondary endpoint was bone turnover.
TREATMENTS
The patients were randomly allocated to receive either 70 mg alendronate (Fosamax ® ; Merck, Sharp & Dohme, Whitehouse Station, NJ, USA) once every 2 weeks plus 0.5 µg alfacalcidol daily (Bon-One ® ; Teijin Pharma, Tokyo, Japan) (treatment group), or 0.5 µg alfacalcidol daily alone (control group). Both regimens were administered for 12 months. All patients were instructed also to have about 800 mg/day dietary calcium plus one daily tablet of 600 mg elemental calcium (Caltrate ® ; Wyeth Pharmaceuticals, Richmond, VA, USA); this also included 400 IU vitamin D 3 . Patients receiving alendronate were instructed to take the tablet in the morning in a fasting state, with around 200 ml water, keep their upper body upright and refrain from any other beverage or food for at least for 30 min. There were no specific instructions for taking the alfacalcidol or elemental calcium.
MEASUREMENT OF BMD
The BMD of the lumbar spine (L1 -L4) and total hip were measured by dual-energy X-ray absorptiometry (GE Lunar Prodigy ® ; GE-Healthcare, Milwaukee, WI, USA) when the study began (baseline) and at 12 months. Percentage changes in BMD were calculated and compared against the World Health Organization's criteria for osteopaenia (Tscore between -1.0 and -2.5). 1
MEASUREMENT OF BONE TURNOVER BIOMARKERS
Serum concentrations of C-terminal telopeptide of type I collagen were measured at baseline and at 12 months of treatment by electrochemiluminescence immunoassay 20 (Modular ® E170 immunoanalyser; Roche Diagnostics, Mannheim, Germany). Concentrations of bone-specific alkaline phosphatase were measured in serum by immunoconcentration and dry chemistry analysis of whole-blood using an adult bone alkaline phosphatase (ABAP) kit according to the manufacturer's instructions (Beijing Zhongsheng Jinyu Diagnostic Technology Co. Ltd, Beijing, China). Briefly, blood was passed through the plasma separator in the test cassette. The separated plasma then went through a reactive membrane containing ABAP specific binding proteins. The substrate for ABAP was added from the kit and the colour change, measured on a colour chart scale provided in the kit, related to the amount of ABAP bound to membrane.
ASSESSMENT OF CALCIUM METABOLISM
Serum concentrations of calcium and phosphate, and the urinary calcium-tocreatinine ratio were measured by automatic biochemical analysis at baseline and at 12 months of treatment. Serum concentrations of 25-hydroxyvitamin D 3 were measured using an enzyme-linked immunosorbent assay kit (Immunodiagnostics Systems, Boldon, UK) at the same time points. L You, Z-Y Sheng, J-Y Chen et al.
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Patients were asked to self-report adverse events. Safety was also assessed by reporting of abnormal laboratory test results, including routine blood chemistry (liver function, kidney function, total cholesterol and glucose) and urinalysis (protein and glucose).
STATISTICAL ANALYSES
The mean ± SD of the data were calculated. Comparisons between the control and treatment groups were made by analysis of variance. Paired sample t-tests were performed to compare the percentage changes from baseline between groups. Fisher's exact test was used to compare the incidence of adverse events. SPSS ® version 11.5 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses and P ≤ 0.05 was regarded as indicating statistical significance.
Results
In total 180 post-menopausal Chinese women of age 40 -70 years were enrolled, with 90 randomly allocated to each study group. A total of 152 (84.4%) patients completed the study -82 (91.1%) in the treatment group and 70 (77.8%) in the control group. The two groups had similar demographic characteristics and baseline values for BMD and biochemical markers of bone turnover ( Table 1) . None of the participants had ever taken medicine to treat osteoporosis before the present study.
CHANGES IN LUMBAR SPINE AND TOTAL HIP BMD
After 12 months of treatment, the mean percentage change from baseline in lumbar spine BMD was statistically significantly higher than baseline in both the treatment group and in the control group (+3.06% versus +1.56%; P < 0.01 for both versus baseline) (Fig. 1A) . The mean percentage increase from baseline for total hip BMD was also statistically significant in the treatment group (+1.91%, P < 0.05 versus baseline), whereas only a slight, non-statistically L You, Z-Y Sheng, J-Y Chen et al. Low-dose alendronate therapy for osteopaenia significant change was seen in the control group (+0.78%) (Fig. 1B) . The changes in lumbar spine BMD and total hip BMD were statistically significant between the treatment and control groups (P < 0.01 for both).
CHANGES IN BIOMARKERS OF BONE TURNOVER
The mean percentage decrease from baseline in serum C-terminal telopeptide of type I collagen was statistically significant at 12 months in the treatment group (-31.4%; P < 0.001 versus baseline), whereas a nonstatistically significant increase from baseline occurred in the control group (+17.9%) ( Fig. 2A) . A statistically significant decrease from baseline in mean percentage bone-specific alkaline phosphatase at 12 24 Low-dose alendronate therapy for osteopaenia months was seen in both the treatment and control groups (-16.2%, P < 0.001 and -6.2% P < 0.05, respectively). The between-group differences at 12 months were statistically significant for both serum C-terminal telopeptide of type I collagen and bonespecific alkaline phosphatase (P < 0.01 and P < 0.05, respectively).
CHANGES IN BIOCHEMICAL PARAMETERS OF CALCIUM METABOLISM
The mean percentage changes in serum concentrations of calcium and 25hydroxyvitamin D 3 , and in the urinary calcium-to-creatinine ratio at 12 months are shown in Fig. 3 . Although the treatment group showed some statistically significant differences compared with baseline (notably significantly decreased serum calcium levels [P < 0.05] and significantly increased serum 25-hydroxyvitamin D 3 levels [P < 0.001]), there were no statistically significant betweengroup differences for any of these biomarkers.
SAFETY
No serious adverse events were reported in either group. Five (5.6%) of the 90 patients in the treatment group and four (4.4%) of the 90 in the control group reported drug-related clinical adverse events (no statistical significant between-group difference in incidence).
These comprised upper gastrointestinal events (n = 4) and muscle pain (n = 1) in the treatment group and upper gastrointestinal events (n = 3) and insomnia (n = 1) in the control group; these patient dropped out of the study and all these clinical adverse events resolved on stopping treatment. Another reason for drop- 24 Low-dose alendronate therapy for osteopaenia outs was difficulty in adhering to the treatment regimen (n = 3 in the treatment group and n = 16 in the control group).
Discussion
The present study showed that administration of 70 mg alendronate once every 2 weeks plus 0.5 µg alfacalcidol daily was associated with increased lumbar spine (L1 -L4) and total hip BMD, and reduced serum levels of bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen. These changes were statistically significant between the alendronate regimen and the control regimen, suggesting efficacy of the alendronate regimen for improvement of BMD and bone turnover.
The changes in BMD and biochemical markers of bone turnover in this study are similar to those of previous studies. 17, 21, 22 Possible reasons why efficacy was maintained with this lower frequency dosing regimen of alendronate are: (i) the drug accumulates in bone and creates a reservoir from which continued release occurs; 23, 24 and (ii) the less frequent dosing may improve compliance and thereby improve efficacy. 25 Eight (8.9%) patients in the treatment group dropped out of the study, compared with 20 (22.2%) in the control group. The overall between-group difference was not statistically significant, however difficulty in compliance in the control group accounted for the majority of the drop-outs in that group (16 cases) . Of the adverse events that caused drop-outs, upper gastrointestinal events may be regarded as the most clinically important. It has been previously shown that these can be ameliorated by a reduction in the frequency of bisphosphonate (alendronate) dosing. 25, 26 An important adverse effect shown by previous studies to be associated with alfacalcidol is hypercalcaemia, 27, 28 although this adverse effect was not seen in the present study. The percentage increases in serum 25hydroxyvitamin D 3 levels in both study groups were very large in the present study, whereas the percentage changes in serum calcium concentrations were very small. In addition, the percentage change in the urinary calcium-to-creatinine ratio in the alendronate group was much lower than in the control group, although there was no statistically significant between-group difference. A possible role for alendronate in decreasing urinary calcium excretion has previously been reported. 29, 30 There were some limitations of the present study. First, it was not a double-blind trial, but an open-labelled study. Bias might, therefore, have affected some of the results. Secondly, history of fragility fractures was self-reported and was not confirmed by plain radiography. Thirdly, although all patients were instructed to have about 800 mg/day dietary calcium during the study period, adherence was not checked and it is not known what their actual intake of dietary calcium was. Fourthly, the effects of the two intervention programmes on fractures could not be assessed because the number of study participants was small. Larger studies with improved patient information need to be carried out to investigate fracture endpoints with the dosing regimens used in this study.
In conclusion, 70 mg alendronate once every 2 weeks plus 0.5 µg alfacalcidol daily was associated with significantly increased lumbar spine and total hip BMD in Chinese post-menopausal women with osteopaenia, along with a marked reduction in the rate of bone turnover. This early antiresorptive drug intervention treatment of osteopaenia might prevent serious outcomes, such as fragility fractures and the low frequency dosing of alendronate might also reduce rates of L You, Z-Y Sheng, J-Y Chen et al. Low-dose alendronate therapy for osteopaenia adverse effects and improve patient compliance. The combination of early intervention and low frequency dosing might also result in medical cost savings.
